|PDI (NASDAQ: PDII) provides commercialization services for established and emerging biopharmaceutical companies. The Company is dedicated to maximizing the return on investment for its clients by providing strategic flexibility; sales, marketing and commercialization expertise; and a philosophy of performance.
PDI operates in two areas, Sales Services and Marketing Services. Our Sales Services include Performance Sales Teams(TM), which are dedicated teams for specific customers; Select Access(TM), our targeted sales solution that leverages an existing infrastructure; and PDI ON DEMAND, innovative sales services that provide rapid, customized sales force solutions tailored to meet local, regional and seasonal needs. Our ... More >>
|05/13/13||PDI Reports 2013 First Quarter Financial Results|
|Management to Host Conference Call Tomorrow, May 14, 2013 at 8:30AM ET
PARSIPPANY, N.J., May 13, 2013 /PRNewswire/ -- PDI, Inc. (Nasdaq: PDII), today reported financial and operational results for the first quarter ended March 31, 2013. Summary financial and operating highlights include:
First quarter 2013 revenue increase of 36% to $42.9 million compared to the same period last year.
Operating income of $2.3 million for the first quarter of 2013, a $2.5 million improvement compared to... |
|05/01/13||PDI, Inc. to Hold First Quarter 2013 Financial Results Conference Call on Tuesday, May 14, 2013|
|PARSIPPANY, N.J., May 1, 2013 /PRNewswire/ -- PDI, Inc. (Nasdaq: PDII) today announced that it will release its first quarter 2013 financial results on Monday, May 13, 2013 after the market close and host a conference call on Tuesday, May 14, at 8:30 am Eastern time to discuss the results.
Tuesday, May 14, 2013
8:30 am Eastern time
(866) 644-4654 (U.S. and Canada) or ... |
|03/13/13||PDI, Inc. Announces $17 Million Multi-Year Sales Contract|
PARSIPPANY, N.J., March 13, 2013 /PRNewswire/ -- PDI, Inc. (Nasdaq: PDII) today announced the signing of a new sales contract which could generate total revenues of up to $17 million over its two-year term. PDI estimates that $5 - $6 million of revenue will be recognized in 2013, beginning in the second quarter. Under the agreement PDI will provide a dedicated team to promote a CNS therapeutic product to neurologists and pain specialists. The agreement also provides an option for contract term... |
|03/06/13||PDI Reports 2012 Fourth Quarter and Year End Financial Results|
|Management Will Host Conference Call Tomorrow March 7, 2013 at 8:30am ET
PARSIPPANY, N.J., March 6, 2013 /PRNewswire/ -- PDI, Inc. (Nasdaq: PDII), today reported financial and operational results for the fourth quarter and year ended December 31, 2012. Summary financial and operating highlights include:
Full year 2012 revenue was $126.9 million compared to $157.3 million for 2011. The company's revenue was lower in 2012 compared to 2011 primarily due to the expiration of certain contract... |
Primary IR Contact
Co-President, Rx Communications